Statement: the primary clinical trial has no interest in tracking the number of lesion fluctuations within its cohorts.
Primary_evidence: Outcome Measurement:    Change in Tumor Size (CTS) From Baseline to the End of Cycle 2   The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant, where the tumor size is the sum of the target lesion measurements at each assessment.   Time frame: Baseline up to end of Cycle 2 (Day 42) Results 1:    Arm/Group Title: LY2523355 + Pegfilgrastim or Filgrastim   Arm/Group Description: LY2523355 administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Dosage determined by calculating participant's body surface area (5 milligrams per meter squared per day [mg/m^2/day]).   Pegfilgrastim or filgrastim administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. Dosage is determined by standard of care.   If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.   Overall Number of Participants Analyzed: 17   Mean (Standard Deviation)   Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.0         (0.08) Results 2:    Arm/Group Title: Ixabepilone   Arm/Group Description: Ixabepilone administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles.   Dosage determined by calculating participant's body surface area (40 mg/m^2).   If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.   Overall Number of Participants Analyzed: 11   Mean (Standard Deviation)   Unit of Measure: log ratio of end of Cycle 2 to baseline  -0.1         (0.37)